Bharat Biotech Helping Ensure TB Vaccine Supply in 70 Countries
Bharat Biotech yesterday announced the partnership with Biofabri, a Spanish biopharmaceutical company, to join forces to develop, manufacture and market a new tuberculosis vaccine in more than 70 countries in Southeast Asia and sub-Saharan Africa.
In a statement, Bharat Biotech said that the vaccine is being manufactured and developed by Biofabri, in close collaboration with the University of Zaragoza, IAVI, and the Tuberculosis Vaccine Initiative (TBVI). MTBVAC, the novel vaccine for TV, has been designed and discovered by Carlos Martín team of the University of Zaragoza.
This agreement between Bharat Biotech and Biofabri would guarantee the worldwide production and the supply of the future vaccine in more than 70 countries with a high TB incidence, such as India, which has the highest TB burden in the world, with a 25 per cent of all cases, the statement said.